More than 25,000 bottles of chlorthalidone — a widely prescribed blood pressure medication — have been pulled from pharmacy shelves after the tablets failed a critical quality check known as dissolution testing. The U.S. Food and Drug Administration recently escalated a September recall of the drug to Class II status, a designation indicating the affected pills could produce temporary or medically reversible health effects. For the millions of Americans who rely on a daily diuretic to keep hypertension in check, the recall raises an urgent, practical question: what actually happens when a blood pressure pill doesn't dissolve the way it's supposed to?
What Is Chlorthalidone and How Does It Work?
Chlorthalidone is a thiazide-type diuretic, commonly called a "water pill," prescribed to treat high blood pressure and to reduce swelling, or edema, caused by heart, kidney, or liver disease. It works by prompting the kidneys to flush excess salt and water out of the body through urine. That process lowers the total volume of fluid circulating in the bloodstream, which in turn reduces the pressure pushing against blood vessel walls.
Unlike some blood pressure medicines that act directly on the heart or blood vessels, chlorthalidone's effectiveness depends entirely on reaching the bloodstream in a predictable, consistent way. The medication is available only by prescription and is usually taken once daily in tablet form, with 25-milligram tablets among the most common doses. A close cousin to hydrochlorothiazide, chlorthalidone is longer-acting and has been a cornerstone of hypertension treatment for decades, remaining a first-line option in many clinical guidelines.
Because chlorthalidone works by removing fluid rather than by directly relaxing arteries, the tablet must first dissolve in the digestive tract so the active ingredient can be absorbed into the bloodstream. If that first step fails, the entire treatment can be compromised — which is precisely why this recall has drawn so much attention.
Why Dissolution Testing Matters More Than You Think
Every pill you swallow is engineered to release its active ingredient at a specific, controlled rate. That release is measured through dissolution testing, a laboratory procedure in which a tablet is submerged in a fluid that mimics conditions in the stomach and intestines, and researchers track how quickly and completely the active pharmaceutical ingredient dissolves into solution.
There are two related but distinct measurements involved. Disintegration testing gauges how fast a tablet physically breaks apart in liquid, while dissolution testing measures how much of the active drug actually enters solution over time. Regulatory agencies such as the FDA require dissolution testing to ensure batch-to-batch consistency and to verify that every pill delivers the correct, predictable dose.
When a tablet fails to dissolve properly, the consequences are straightforward. The body cannot absorb medication that never enters solution, so a pill that doesn't break down may pass through the digestive system without releasing its full dose. The result is a weaker — or in some cases essentially ineffective — dose. For a blood pressure medication like chlorthalidone, that could mean a patient unknowingly receives far less treatment than their prescription intended.
Inside the Recall: What Went Wrong With the Tablets
The recall involves chlorthalidone tablets manufactured by Inventia Healthcare Limited, a Massachusetts-based company. According to the FDA, the affected tablets "failed dissolution specifications," meaning laboratory testing showed they did not dissolve as required by regulatory standards.
The recall unfolded in two waves during 2026. The first, announced in June, covered 11,460 bottles of 25-milligram chlorthalidone tablets. A second, larger recall followed in September, covering an additional 13,567 bottles. Combined, the two actions account for more than 25,000 bottles of the medication distributed nationwide.
The most recent recall applies specifically to Chlorthalidone Tablets USP, 25 mg, sold in 100-count and 1,000-count bottles. The affected product carries National Drug Code (NDC) 64980-599-01, batch number RISA24002, and an expiration date of April 2027. Because the tablets were distributed to pharmacies across the country, patients in virtually every state are being urged to check their prescription bottles.
What a Class II Recall Actually Means
The FDA sorts recalls into three tiers based on the level of risk a product poses. A Class I recall is the most serious, reserved for products with a reasonable probability of causing serious adverse health consequences or death. A Class II recall — the category assigned to the chlorthalidone recall — covers situations in which use of the product "may cause temporary or medically reversible adverse health consequences" or where the probability of serious harm is remote. A Class III recall involves products unlikely to cause any adverse health effects.
The manufacturer initiated the September chlorthalidone recall voluntarily on September 3, and the FDA assigned the Class II designation on September 17. The classification upgrade does not mean the medication is deadly. Rather, it reflects a more subtle risk: a pill that fails to dissolve could deliver an unpredictable dose, potentially leaving a patient's blood pressure inadequately controlled without their knowledge.
What Should Patients Do Right Now?
Health experts and the FDA emphasize one piece of advice above all others: do not stop taking chlorthalidone on your own. Abruptly discontinuing a blood pressure medication can trigger a dangerous spike in blood pressure, sometimes called rebound hypertension, which carries its own serious risks, including stroke and heart attack.
Instead, patients should check the label on their prescription bottle. If the bottle lists NDC 64980-599-01, batch number RISA24002, or an expiration date of April 2027, it may be part of the recall. Anyone who believes their medication is affected should contact a pharmacist or prescribing doctor to discuss next steps, which may include receiving a replacement prescription from an unaffected lot.
Because chlorthalidone is a long-acting diuretic, any change in medication should be made under medical supervision so that blood pressure remains stable throughout the transition. Pharmacists can often verify a lot number quickly and confirm whether a specific bottle is subject to the recall.
The Bottom Line: Key Points to Remember
- More than 25,000 bottles of 25 mg chlorthalidone tablets have been recalled across two separate actions in 2026.
- The recalls were triggered by "failed dissolution specifications," meaning the pills did not dissolve properly during testing.
- The FDA classified the September recall as Class II, indicating a risk of temporary or medically reversible health effects.
- The affected product is batch number RISA24002 (NDC 64980-599-01), with an expiration date of April 2027.
- Patients should not stop the medication abruptly; instead, they should check their bottle and consult a pharmacist or doctor if affected.
